EGFR and non-small cell lung carcinoma: In the present work, although we were not able to reconfirm the inhibitory effect of pterostilbene alone on Src and MET activation 15, or other downstream components (Figure 2C), the combination of osimertinib plus pterostilbene was synergistic in five-, and downregulated the activation of STAT3, Src-YAP1 and CDCP1 in two EGFR-mutation positive NSCLC cell lines (Figure 4B).